InnotiveDx Receives £1 Million Grant To Combat Antimicrobial Resistance

InnotiveDx Secures Significant Grant to Enhance UTI Diagnostic Solutions

Innotive Diagnostics, known as InnotiveDx, has announced a major achievement: the acquisition of a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy). This funding will be pivotal for the development of their innovative rapid diagnostic system for urinary tract infections (UTIs).

The Importance of Addressing UTIs

UTIs are a prevalent health issue affecting hundreds of millions globally, contributing significantly to the consumption of antibiotics—over 20% of prescriptions issued annually. This excessive use of antibiotics not only impacts patient health but also escalates the challenges posed by antimicrobial resistance (AMR), making it one of the most pressing healthcare concerns today. Global healthcare systems bear the financial burden of unplanned hospital admissions due to UTIs, amounting to billions in healthcare costs each year.

Cutting-Edge Technology

InnotiveDx's solution aims to change the landscape of UTI diagnosis. Their technology promises to deliver highly accurate bacterial identification and antimicrobial susceptibility testing results in under 60 minutes. Impressively, recent assessments have shown that their laboratory-based assays achieve an accuracy rate exceeding 96% in blinded evaluations. With the backing of the PACE grant, the company anticipates conducting extensive evaluations of their newly automated prototypes against thousands of clinical specimens, paving the way for real-world clinical pilot studies.

Voice from Leadership

James Mainwaring, the Chief Commercial and Operating Officer at InnotiveDx, expressed his enthusiasm about the grant, stating, "We are delighted to have been awarded this £1m PACE grant; it is a tremendous validation of our technology, vision and all the hard work our team has put in since spinout. AMR is one of the most pressing challenges humanity faces, and we are looking forward to tackling this problem with like-minded individuals from PACE and the wider portfolio of companies."

Dr. Beverley Isherwood, the PACE Programme Director, praised InnotiveDx’s work, saying, "Congratulations to Innotive Diagnostics! We are delighted to welcome them into the PACE portfolio after a highly competitive diagnostics funding call. PACE will support InnotiveDx in advancing InnotiveUTI using a collaborative approach, helping them generate the essential validation data required to position their project for onward development, funding and investment."

Collaborative Efforts Against AMR

The PACE initiative is one of the United Kingdom’s significant collaborations aimed at tackling the growing challenges posed by antimicrobial resistance through the support of innovative drug and diagnostic discovery. By integrating efforts with organizations like PACE, InnotiveDx can work on creating essential solutions that not only enhance patient outcomes but also contribute to broader public health goals.

In not just providing timely diagnosis but also addressing treatment efficacy, InnotiveDx is setting new standards in the healthcare field. As they move towards clinical implementation, the company remains committed to making tangible impacts in the fight against AMR, ensuring patients receive the necessary treatment without delay.

In conclusion, this grant not only signifies a milestone for InnotiveDx but also highlights the critical importance of innovative diagnostics in managing UTIs more effectively in a world grappling with antimicrobial resistance. With such advancements, there is hope for improved patient care and reduced strain on healthcare systems worldwide.